KBC Group NV Increases Holdings in Exelixis, Inc. (NASDAQ:EXEL)

KBC Group NV lifted its position in Exelixis, Inc. (NASDAQ:EXEL) by 46.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,514 shares of the biotechnology company’s stock after buying an additional 3,332 shares during the period. KBC Group NV’s holdings in Exelixis were worth $350,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the company. Blue Trust Inc. grew its stake in shares of Exelixis by 134.7% during the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 8,208 shares during the period. Fifth Third Bancorp grew its position in Exelixis by 16.1% during the fourth quarter. Fifth Third Bancorp now owns 3,231 shares of the biotechnology company’s stock valued at $108,000 after buying an additional 449 shares during the period. DGS Capital Management LLC purchased a new stake in Exelixis during the fourth quarter valued at approximately $276,000. Exchange Traded Concepts LLC boosted its stake in shares of Exelixis by 125.9% during the 4th quarter. Exchange Traded Concepts LLC now owns 90,858 shares of the biotechnology company’s stock worth $3,026,000 after acquiring an additional 50,640 shares during the last quarter. Finally, Inspire Investing LLC grew its position in shares of Exelixis by 25.0% during the 4th quarter. Inspire Investing LLC now owns 36,659 shares of the biotechnology company’s stock valued at $1,221,000 after acquiring an additional 7,331 shares during the period. Institutional investors own 85.27% of the company’s stock.

Exelixis Stock Performance

NASDAQ EXEL opened at $33.15 on Monday. The stock has a 50 day moving average price of $34.68 and a 200-day moving average price of $30.18. Exelixis, Inc. has a one year low of $20.01 and a one year high of $37.59. The company has a market capitalization of $9.47 billion, a P/E ratio of 21.25, a P/E/G ratio of 0.72 and a beta of 0.53.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Piper Sandler lifted their target price on Exelixis from $36.00 to $37.00 and gave the company an “overweight” rating in a research report on Monday, January 13th. UBS Group lifted their price objective on Exelixis from $30.00 to $34.00 and gave the company a “neutral” rating in a research report on Tuesday, January 28th. BMO Capital Markets lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and increased their target price for the stock from $36.00 to $40.00 in a report on Friday, December 20th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Exelixis in a research note on Monday, January 27th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $34.00 price target on shares of Exelixis in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $36.06.

Insider Activity at Exelixis

In related news, EVP Dana Aftab sold 96,986 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $35.00, for a total value of $3,394,510.00. Following the completion of the sale, the executive vice president now directly owns 498,945 shares in the company, valued at $17,463,075. This trade represents a 16.27 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the transaction, the executive vice president now owns 486,059 shares in the company, valued at $17,823,783.53. This trade represents a 10.99 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 208,574 shares of company stock valued at $7,376,374. Insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.